Last reviewed · How we verify
Paroxetine + relaxation
Paroxetine inhibits serotonin reuptake to elevate mood and reduce anxiety, while relaxation techniques provide behavioral reinforcement of anxiolytic effects.
Paroxetine inhibits serotonin reuptake to elevate mood and reduce anxiety, while relaxation techniques provide behavioral reinforcement of anxiolytic effects. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.
At a glance
| Generic name | Paroxetine + relaxation |
|---|---|
| Sponsor | University of Göttingen |
| Drug class | SSRI (Selective Serotonin Reuptake Inhibitor) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the reuptake of serotonin at the presynaptic neuron, increasing serotonin availability in the synaptic cleft. The addition of relaxation therapy as a combined intervention enhances therapeutic outcomes by providing complementary behavioral and physiological stress-reduction mechanisms, potentially improving treatment efficacy and patient outcomes in anxiety and mood disorders.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Panic disorder
- Social anxiety disorder
- Obsessive-compulsive disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Sexual dysfunction
- Somnolence
- Tremor
- Diarrhea
Key clinical trials
- Building Ukraine's Strength in PTSD Treatment and Research (NA)
- Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study
- Stepped Care for Depression and Musculoskeletal Pain (PHASE4)
- Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder (PHASE4)
- Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paroxetine + relaxation CI brief — competitive landscape report
- Paroxetine + relaxation updates RSS · CI watch RSS
- University of Göttingen portfolio CI